MX356278B - Combinacion farmaceutica que comprende un inhibidor de fosfatidilinositol 3-cinasa y un inhibidor de aromatasa. - Google Patents
Combinacion farmaceutica que comprende un inhibidor de fosfatidilinositol 3-cinasa y un inhibidor de aromatasa.Info
- Publication number
- MX356278B MX356278B MX2015003657A MX2015003657A MX356278B MX 356278 B MX356278 B MX 356278B MX 2015003657 A MX2015003657 A MX 2015003657A MX 2015003657 A MX2015003657 A MX 2015003657A MX 356278 B MX356278 B MX 356278B
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- pharmaceutical combination
- phosphatidylinositol
- treatment
- aromatase inhibitor
- Prior art date
Links
- 229940122815 Aromatase inhibitor Drugs 0.000 title abstract 3
- 239000003886 aromatase inhibitor Substances 0.000 title abstract 3
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- -1 urea derivative compound Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261703533P | 2012-09-20 | 2012-09-20 | |
| US201261708070P | 2012-10-01 | 2012-10-01 | |
| PCT/US2013/060292 WO2014047109A1 (en) | 2012-09-20 | 2013-09-18 | Pharmaceutical combination comprising a phosphatidylinositol 3-kinase inhibitor|and an aromatase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015003657A MX2015003657A (es) | 2015-06-05 |
| MX356278B true MX356278B (es) | 2018-05-22 |
Family
ID=49263471
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015003657A MX356278B (es) | 2012-09-20 | 2013-09-18 | Combinacion farmaceutica que comprende un inhibidor de fosfatidilinositol 3-cinasa y un inhibidor de aromatasa. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9532982B2 (enExample) |
| EP (1) | EP2897644B1 (enExample) |
| JP (1) | JP6212563B2 (enExample) |
| KR (1) | KR102220965B1 (enExample) |
| CN (1) | CN104661681B (enExample) |
| AU (1) | AU2013318205B2 (enExample) |
| BR (1) | BR112015004152A2 (enExample) |
| CA (1) | CA2880506C (enExample) |
| CY (1) | CY1120984T1 (enExample) |
| DK (1) | DK2897644T3 (enExample) |
| ES (1) | ES2686689T3 (enExample) |
| HR (1) | HRP20181413T1 (enExample) |
| HU (1) | HUE040520T2 (enExample) |
| IN (1) | IN2015DN00735A (enExample) |
| LT (1) | LT2897644T (enExample) |
| MX (1) | MX356278B (enExample) |
| PL (1) | PL2897644T3 (enExample) |
| PT (1) | PT2897644T (enExample) |
| RU (1) | RU2651023C2 (enExample) |
| SI (1) | SI2897644T1 (enExample) |
| WO (1) | WO2014047109A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3140427B1 (en) * | 2014-05-09 | 2020-10-14 | Memorial Sloan Kettering Cancer Center | Biomarkers for response to pi3k inhibitors |
| CN118593514B (zh) * | 2024-05-09 | 2025-05-27 | 西南医科大学附属医院 | 芳香化酶抑制剂在制备治疗黑色素瘤药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100298286A1 (en) * | 2007-12-20 | 2010-11-25 | Novartis Ag | Organic Compounds |
| PE20091523A1 (es) * | 2007-12-20 | 2009-10-29 | Novartis Ag | Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k) |
| JP2011525535A (ja) * | 2008-06-24 | 2011-09-22 | 武田薬品工業株式会社 | ＰＩ３Ｋ／ｍＴＯＲ阻害剤 |
| UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| US8293753B2 (en) * | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
-
2013
- 2013-09-18 EP EP13770771.7A patent/EP2897644B1/en active Active
- 2013-09-18 CN CN201380049140.1A patent/CN104661681B/zh active Active
- 2013-09-18 DK DK13770771.7T patent/DK2897644T3/en active
- 2013-09-18 BR BR112015004152A patent/BR112015004152A2/pt not_active IP Right Cessation
- 2013-09-18 ES ES13770771.7T patent/ES2686689T3/es active Active
- 2013-09-18 LT LTEP13770771.7T patent/LT2897644T/lt unknown
- 2013-09-18 CA CA2880506A patent/CA2880506C/en active Active
- 2013-09-18 IN IN735DEN2015 patent/IN2015DN00735A/en unknown
- 2013-09-18 RU RU2015111171A patent/RU2651023C2/ru active
- 2013-09-18 AU AU2013318205A patent/AU2013318205B2/en active Active
- 2013-09-18 PT PT13770771T patent/PT2897644T/pt unknown
- 2013-09-18 US US14/429,367 patent/US9532982B2/en active Active
- 2013-09-18 PL PL13770771T patent/PL2897644T3/pl unknown
- 2013-09-18 HR HRP20181413TT patent/HRP20181413T1/hr unknown
- 2013-09-18 JP JP2015533141A patent/JP6212563B2/ja active Active
- 2013-09-18 MX MX2015003657A patent/MX356278B/es active IP Right Grant
- 2013-09-18 SI SI201331154T patent/SI2897644T1/sl unknown
- 2013-09-18 KR KR1020157006708A patent/KR102220965B1/ko active Active
- 2013-09-18 WO PCT/US2013/060292 patent/WO2014047109A1/en not_active Ceased
- 2013-09-18 HU HUE13770771A patent/HUE040520T2/hu unknown
-
2018
- 2018-09-05 CY CY181100927T patent/CY1120984T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015004152A2 (pt) | 2017-07-04 |
| ES2686689T3 (es) | 2018-10-19 |
| HUE040520T2 (hu) | 2019-03-28 |
| EP2897644B1 (en) | 2018-06-06 |
| RU2651023C2 (ru) | 2018-04-18 |
| IN2015DN00735A (enExample) | 2015-07-10 |
| JP2015532927A (ja) | 2015-11-16 |
| US20150231124A1 (en) | 2015-08-20 |
| CA2880506A1 (en) | 2014-03-27 |
| CN104661681B (zh) | 2018-07-03 |
| EP2897644A1 (en) | 2015-07-29 |
| US9532982B2 (en) | 2017-01-03 |
| KR20150056778A (ko) | 2015-05-27 |
| RU2015111171A (ru) | 2016-11-10 |
| AU2013318205A1 (en) | 2015-02-26 |
| PL2897644T3 (pl) | 2018-11-30 |
| KR102220965B1 (ko) | 2021-02-26 |
| CN104661681A (zh) | 2015-05-27 |
| MX2015003657A (es) | 2015-06-05 |
| AU2013318205B2 (en) | 2016-05-19 |
| SI2897644T1 (sl) | 2018-10-30 |
| CA2880506C (en) | 2021-04-20 |
| LT2897644T (lt) | 2018-09-25 |
| DK2897644T3 (en) | 2018-09-10 |
| HRP20181413T1 (hr) | 2018-10-19 |
| CY1120984T1 (el) | 2019-12-11 |
| WO2014047109A1 (en) | 2014-03-27 |
| JP6212563B2 (ja) | 2017-10-11 |
| PT2897644T (pt) | 2018-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201290919A1 (ru) | Индазольные соединения и их применение | |
| MX2020003174A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer. | |
| BR112015009168A2 (pt) | composto de fórmula estrutural xi, uso de um composto, composição farmacêutica, método de tratamento de uma doença mediada pela pde4 em um sujeito, método de modulação de uma função mediada pela pde4 em um sujeito, método de alcançar um efeito em um paciente e método para inibir a pde4 | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| EA201692506A3 (ru) | Ингибиторы репликации вирусов гриппа | |
| BR112015016997A2 (pt) | composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama | |
| PH12014502757B1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| MX382162B (es) | Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer. | |
| EA201691155A1 (ru) | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств | |
| BR112015026238A2 (pt) | tratamento de câncer com dihidropirazino-pirazinas | |
| MX2013003638A (es) | Tratamiento en combinacion para rosacea. | |
| EA201491500A1 (ru) | Способы лечения фиброза | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| BR112013010136A2 (pt) | vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma | |
| MX394452B (es) | Inhibicion de la actividad de olig2. | |
| MX2014004559A (es) | Derivados de 2-carboxamida cicloamino urea en combinacion con inhibidores de hsp90 para el tratamiento de enfermedades proliferativas. | |
| MX2016001536A (es) | Derivados de urea de piperidinas. | |
| MX2015012455A (es) | Metodo para el tratamiento de la enfermedad de higado graso. | |
| PH12014502065A1 (en) | Vesicular formulations | |
| MX394015B (es) | Inhibición de la actividad de la olig2. | |
| BR102012028120B8 (pt) | Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento | |
| MX356278B (es) | Combinacion farmaceutica que comprende un inhibidor de fosfatidilinositol 3-cinasa y un inhibidor de aromatasa. | |
| EA201201404A1 (ru) | Триазолы как ингибиторы кбв (кинезин-белок веретена) | |
| GB201004761D0 (en) | Method | |
| BR112017002449A2 (pt) | tratamento de sintomas associados com terapia de privação androgênica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |